Transfusion in Anemic Patients With Acute Coronary Syndromes: A Population-Based Cohort Study
In patients hospitalized for ACS who experience nadir Hb levels between 6.0 and 8.9g/dL, RBC transfusion was associated with a reduction in the composite event of all-cause death and hospitalization for MI within 30-days after hospital discharge.
Authors
- Dennis T. Ko (ORCID: https://orcid.org/0000-0001-6840-8051)
- Duminda N. Wijeysundera (ORCID: https://orcid.org/0000-0002-5897-8605)
- Maneesh Sud (ORCID: https://orcid.org/0000-0003-1936-5133)
- Peter C. Austin (ORCID: https://orcid.org/0000-0003-3337-233X)
- Gregory M. T. Hare (ORCID: https://orcid.org/0000-0003-4641-4818)
- Nadine Shehata (ORCID: https://orcid.org/0000-0002-9267-6256)
- C. David Mazer (ORCID: https://orcid.org/0000-0003-2566-4308)
- Karim Shiraz Ladha (ORCID: https://orcid.org/0000-0001-7303-2458)
- Atul Sivaswamy
- Subodh Verma (ORCID: https://orcid.org/0000-0002-4018-8533)
- Olivia Haldenby
- Nikhil Mistry
Institutions
- St. Michael's Hospital (CA)
- Sunnybrook Health Science Centre (CA)
- Sinai Health System (CA)
- Institute for Clinical Evaluative Sciences (CA)
Publication Details
- Journal
- Canadian Journal of Cardiology
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1016/j.cjca.2024.10.012
- Citations
- 3
- Primary Topic
- Blood transfusion and management
- Type
- article
- Field-Weighted Citation Impact
- 0.67
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- World Bank Group
- Institute for Clinical Evaluative Sciences
- Amarin Corporation
- University of Toronto
- Novo Nordisk
- HLS Therapeutics